Plus Therapeutics’ (PSTV) “Hold” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their hold rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note published on Tuesday morning, MarketBeat.com reports.

Several other analysts have also issued reports on PSTV. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $1.00 price target (down from $2.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. Finally, Lake Street Capital assumed coverage on Plus Therapeutics in a report on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Plus Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $5.60.

Plus Therapeutics Price Performance

Shares of NASDAQ:PSTV opened at $3.56 on Tuesday. The business’s 50 day moving average price is $0.33 and its 200-day moving average price is $0.48. Plus Therapeutics has a 1 year low of $3.23 and a 1 year high of $30.50. The firm has a market capitalization of $610.72 million, a price-to-earnings ratio of -2.87 and a beta of 1.03.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings results on Thursday, March 12th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.28. The company had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $1.23 million. On average, sell-side analysts expect that Plus Therapeutics will post -2.3 earnings per share for the current year.

Institutional Trading of Plus Therapeutics

A number of hedge funds have recently bought and sold shares of PSTV. L1 Global Manager Pty Ltd acquired a new position in shares of Plus Therapeutics during the 4th quarter worth approximately $1,167,000. Geode Capital Management LLC lifted its position in Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after buying an additional 589,544 shares in the last quarter. Jane Street Group LLC purchased a new position in Plus Therapeutics during the fourth quarter worth approximately $525,000. Altium Capital Management LLC acquired a new position in Plus Therapeutics during the third quarter worth $628,000. Finally, Virtu Financial LLC acquired a new position in Plus Therapeutics during the fourth quarter worth $254,000. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.